证券代码：300233 证券简称：金城医药 公告编号：2026-008 山东金城医药集团股份有限公司 关于子公司参与国家组织集采药品协议期满品种接续 采购拟中选的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）控股子公司广东金城 金素制药有限公司（以下简称"金城金素"）及全资子公司上海金城素智药业有 限公司（以下简称"金城素智"）参加了国家组织集采药品协议期满品种接续采 购办公室组织的国家组织集采药品协议期满品种接续采购的投标工作，头孢曲松 钠注射剂、头孢他啶注射剂等七个品种拟中选本次接续采购。现将相关情况公告 如下:一、拟中选产品情况 | | 钠他唑巴 | 坦组成的复方药物，适用于治疗由下列病症中指定细菌的易感分离 | | --- | --- | --- | | | 坦钠注射 | 株引起的中度至重度感染。如：社区获得性肺炎、医院获得性肺炎、 | | | 剂 | 泌尿道感染、腔内感染、骨与关节感染及多种细菌混合感染等。 | | | 左氧氟沙 | 适用于治疗或预防已证明或高度怀疑由敏感细菌引起的感染。如： | ...

Group 1 - The core point of the article is that Jincheng Pharmaceutical (300233) reported a total of 29,199 shareholders as of January 30, 2026 [1]

Summary of Industry Reports Industry: Pharmaceutical and Biotechnology Key Points from Document 1 1. **Raw Material Supply Changes**: The supply of raw materials is accelerating, with a focus on subsequent volume and price changes [1] 2. **Global GLP-1 Landscape**: The global GLP-1 landscape is continuously evolving, and Chinese companies are still pursuing international expansion [1] 3. **Small Nucleic Acid Sector**: Leading companies are gradually entering the small nucleic acid field, with market progress expected to drive the development of supporting industrial chains [1] 4. **Retail Pharmaceutical Market Outlook**: The retail pharmaceutical market is expected to improve by Q4 2025, with an enhanced positioning of chain pharmacies [1] 5. **Value of Oral Immunomodulatory Drugs**: Emphasis on the market value of oral immunomodulatory drugs [1] 6. **Investment Recommendations**: Recommended companies include Chuaning Biological, with attention to Lianbang Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, as well as synthetic biology companies [1] 7. **CXO Order Trends**: Positive trends in CXO orders and rising prices for safety evaluation orders, with recommendations for Yinos and Zhaoyan New Drug, and recommendations for Weiya Biological and Puris [1] Key Points from Document 2 1. **Small Nucleic Acids Breakthrough**: Continuous breakthroughs in small nucleic acids, with ongoing progress in external authorizations by Chinese companies, recommending Yuekang Pharmaceutical and Sunshine Novo [2] 2. **Self-Immunity Field**: Focus on breakthroughs in oral directions and difficult-to-treat areas like UC/IBD, recommending Yahong Pharmaceutical and Yifang Biological [2] 3. **GLP-1 Weight Loss Authorizations**: Recommendations for Zhongsheng Pharmaceutical in the GLP-1 weight loss field, with attention to Lianbang Pharmaceutical and Shiyao Group [2] 4. **ZAP-X Radiation Therapy Equipment**: Initiation of domestic clinical research for ZAP-X radiation therapy equipment, recommending Baiyang Pharmaceutical [2] 5. **Policy Support for Brain-Computer Interface Technology**: Support for the development of invasive brain-computer interfaces, recommending Meihao Medical and Botuo Biological, with accelerated approvals for non-invasive devices, focusing on Xiangyu Medical and Kefu Medical [2] 6. **High-Value Medical Device Exports**: Breakthroughs in exports of high-value medical consumables, with attention to Chunli Medical, Aikang Medical, Nanwei Medical, and Baixin An [2] 7. **AI in Healthcare**: Accelerated applications of AI in healthcare, reshaping application scenarios and bringing changes in industrial chain value, recommending Anbiping and focusing on Yuyue Medical and Meinian Health [2] 8. **Chain Pharmacy Industry**: Industry consolidation in chain pharmacies, with policy support for enhanced positioning, recommending Yifeng Pharmacy and Laobaiqing, with attention to Yixintang [2]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., has been re-certified as a high-tech enterprise, allowing it to continue paying a corporate income tax rate of 15% from 2025 to 2027 [1] Group 1 - The re-certification was conducted by the Guangdong Provincial Department of Science and Technology, the Guangdong Provincial Department of Finance, and the State Taxation Administration of Guangdong Province [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., has received a new High-tech Enterprise Certificate, valid for three years, following the expiration of the previous certificate [1] Group 1 - The new High-tech Enterprise Certificate was issued by the Guangdong Provincial Department of Science and Technology, the Guangdong Provincial Department of Finance, and the State Taxation Administration of Guangdong Province [1] - This re-certification indicates the company's ongoing commitment to innovation and technology development in the pharmaceutical industry [1] - The certificate number for the new recognition is GR202544001413 [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）控股子公司广东金城金素 制药有限公司（以下简称"金城金素"）于近日收到由广东省科学技术厅、广东省财 政厅、国家税务总局广东省税务局联合颁发的《高新技术企业证书》，证书编号： GR202544001413，有效期三年。 证券代码：300233 证券简称：金城医药 公告编号：2026-007 山东金城医药集团股份有限公司 关于子公司通过高新技术企业重新认定的公告 本次系金城金素在原《高新技术企业证书》有效期满后进行的重新认定。根据国 家有关规定，金城金素自高新技术企业认定后连续三年内（2025年至2027年）可继续 享受国家关于高新技术企业的税收优惠政策，即按15%的税率缴纳企业所得税。 本次金城金素通过高新技术企业重新认定不会影响公司2025年度的经营业绩。 特此公告。 山东金城医药集团股份有限公司董事会 2026 年 2 月 6 日 ...

Core Viewpoint - Jincheng Pharmaceutical experienced a decline of 2.29% on January 30, with a trading volume of 114 million yuan, indicating a challenging market environment for the company [1]. Financing Summary - On January 30, Jincheng Pharmaceutical had a financing buy-in amount of 13.56 million yuan and a financing repayment of 13.38 million yuan, resulting in a net financing buy of 189,100 yuan [1]. - The total financing and securities balance for Jincheng Pharmaceutical reached 417 million yuan, with the financing balance accounting for 7.05% of the circulating market value, which is above the 50th percentile level over the past year [1]. - In terms of securities lending, there were no shares repaid on January 30, with 300 shares sold short, amounting to 4,611 yuan at the closing price [1]. Company Performance - As of January 20, the number of shareholders for Jincheng Pharmaceutical increased by 4.95% to 29,100, while the average circulating shares per person decreased by 4.72% to 12,768 shares [2]. - For the period from January to September 2025, Jincheng Pharmaceutical reported a revenue of 1.932 billion yuan, a year-on-year decrease of 23.19%, and a net profit attributable to shareholders of 31.58 million yuan, down 79.10% year-on-year [2]. Dividend and Shareholding Information - Since its A-share listing, Jincheng Pharmaceutical has distributed a total of 933 million yuan in dividends, with 323 million yuan distributed over the past three years [3]. - As of September 30, 2025, among the top ten circulating shareholders, the "Fuguo Precision Medical Flexible Allocation Mixed A" fund is the fourth largest shareholder with 4.961 million shares, while "Hong Kong Central Clearing Limited" is the eighth largest with 3.336 million shares, having decreased by 2.135 million shares from the previous period [3].

证券日报网讯 1月30日，金城医药发布公告称，控股股东金城实业将其所持13540000股公司股份质押展 期至2026年7月30日，占其持股17.24%，对应公司总股本3.53%，质权人为国泰海通证券股份有限公 司，不涉及新增融资。 （编辑 袁冠琳） ...

Group 1 - The company Jin Cheng Pharmaceutical announced on January 30 that it has recognized an asset impairment provision totaling 55.6624 million yuan, which will be included in the company's 2025 financial results [1] - This impairment is expected to reduce the net profit attributable to shareholders of the listed company by approximately 49.6106 million yuan for the year 2025 [1] - The total equity attributable to shareholders of the listed company will also decrease by about 49.6106 million yuan [1] Group 2 - The nuclear power construction industry is experiencing a surge, with equipment manufacturers reportedly busy with orders scheduled until 2028 [1] - Employees are working in three shifts, and production lines are operating 24 hours a day to meet the high demand [1]

Core Viewpoint - Jincheng Pharmaceutical has announced an annual performance forecast indicating a significant decline in net profit for 2025, with expectations of a decrease of 73.07% to 79.67% year-on-year [1] Financial Performance Summary - The company anticipates a net profit attributable to shareholders of 40 million to 53 million yuan for 2025, which represents a substantial decrease compared to the previous year [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 28 million and 37 million yuan, reflecting a year-on-year decline of 79.43% to 84.44% [1] Reasons for Performance Change - The primary reasons for the decline in performance include: 1. A slowdown in product market demand, intense industry competition, and the impact of national centralized procurement policies, leading to a decrease in both prices and sales volume for certain products in the intermediate and formulation segments [1] 2. An increase in asset impairment provisions for 2025 compared to the previous year, in response to industry and market changes [1] 3. The need for the company's subsidiaries, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. and its wholly-owned subsidiary Guangdong Landu Pharmaceutical Co., Ltd., to pay back taxes from previous years [1] - The impact of non-recurring gains and losses on net profit is estimated to be between 12 million and 16 million yuan [1]